Umut Meriç – General Manager, Chiesi Turkey
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Chiesi, founded in 1935, serves patients in 60 countries, with a total turnover of EUR 1.3 billion per year, in the areas of respiratory disease, neonatal intensive care, allergy, and cardiology. R&D efforts are currently targeting conditions such as cystic fibrosis, organ transplantation, and rare diseases, with approximately 20 percent of annual turnover invested in R&D each year. Chiesi Turkey was founded in 2007, and has grown quickly to become the 50th ranked pharmaceutical company in the market.
Contact Details
Büyükdere Cad. No: 122 Özsezen Business Centre Block C Floor: 3
Esentepe – Sisli 34394 Istanbul / Turkey
Tel: 0212 370 91 00 –
Fax: 0212 370 91 27
info.tr@chiesi.co I
Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Murat Barlas, the longest serving board member for the Turkish Pharmaceutical Manufacturers Association, discusses the need for a new perspective in government-industry relations in the Turkish pharmaceutical industry, and the…
The Turkish minister of labour and social security comments on the country’s deep commitment to providing for the health of citizens while maintaining sustainability and continuous improvement of services. How…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Turkey is a key market in the region for Servier, says general manager Philippe Méa, largely due to the country’s relatively strong and stable vision for the healthcare industry. The…
Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness…
Bayer Turkey’s healthcare division head discusses how the company adapted to the post 2009 pharmaceutical pricing environment by shrinking their portfolio and focusing strongly on key growth products, launched recently…
Medipol hospital’s medical director discusses the private institution’s current role in the Turkish healthcare system, and their plans for expansion in the coming years. How did Medipol come into existence,…
Professor Burak Erman, the leader of the Drug Research Center at Koç University, and his colleague Hakan Orer, discuss the early activities of the center as a catalyst for collaboration…
Janssen’s MD in Turkey discusses how true innovation is still recognized in Turkey, and how products that meet unmet medical needs are given early access to the country and reimbursement.…
IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such…
The managing director of Otsuka’s 50-50 joint venture with Turkish giant Abdi Ibrahim, Abdi Ibrahim Otsuka, discusses the mutual advantage the companies can offer each other, and branding Abdi Ibrahim…
Turkey’s Minister of Health discusses the major achievements of his party in the area of healthcare since 2003, and the key priorities for the country’s healthcare system moving forward. During…
See our Cookie Privacy Policy Here